Theraly Fibrosis is a biotechnology company focused on developing innovative treatments for chronic pancreatitis, specifically through its lead product, TLY012. The company has received significant funding, including a $3.9 million SBIR Phase II grant, which underscores its commitment to advancing therapeutic solutions for conditions related to fibrosis. This financial backing is indicative of the potential market value and the scientific merit of its research, positioning Theraly as a key player in the life sciences sector.

The company operates within the framework of the Maryland Innovation Initiative (MII), which aims to facilitate the commercialization of research from Maryland's academic institutions. This initiative supports the transition of promising technologies from universities to the market, emphasizing technology validation and market assessment. By leveraging resources from TEDCO and collaborating with various research organizations, Theraly is well-equipped to navigate the complexities of bringing its innovative therapies to fruition, ultimately addressing unmet medical needs in chronic pancreatitis and related conditions.

United States

TEDCO enhances economic empowerment growth through the fostering of an inclusive entrepreneurial innovation ecosystem. TEDCO identifies, invests in, and helps grow technology companies in Maryland.
Take our customer satisfaction survey and let us know how we're doing: https://tedco.tfaforms.net/40 

Theraly

Company Details